🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hollis Viray

Beth Israel Deaconess Medical Center

ORCID: 0000-0002-5668-0346

Also affiliated with Harvard University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.757Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079
Top 27%
0.757DataRank
Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

Papers

Driven by 5 papers — median percentile 73. Top paper: “A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice”.

A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

Cancers(2024)10.3390/cancers16061079
Top 27%
0.757DataRank
Top 27%17 citations

Andrew J. Piper‐Vallillo, Page Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari +4 more

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100051
N/A
0DataRank · unranked
81 citations

Carol Gergis, Hollis Viray, Andreas Varkaris, Masanori Fujii, Deepa Rangachari +5 more

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000697
N/A
0DataRank · unranked
48 citations

Andreas Varkaris, Hollis Viray, Paul A. VanderLaan, Deepa Rangachari, Daniel B. Costa +1 more

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

Translational Lung Cancer Research(2023)10.21037/tlcr-23-98
N/A
0DataRank · unranked
33 citations

Emmeline C. Academia, Hollis Viray, Deepa Rangachari, Susumu Kobayashi, Paul A. VanderLaan +2 more

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100614
N/A
0DataRank · unranked
11 citations

William O. Shaffer, Hollis Viray, Deepa Rangachari, Paul A. VanderLaan, Susumu Kobayashi +2 more